These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 8948764

  • 1. [Tobramycin--clinical pharmacology and chemotherapy].
    Periti P.
    J Chemother; 1996 Jan; 8 Suppl 1():3-30. PubMed ID: 8948764
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T.
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [Abstract] [Full Text] [Related]

  • 7. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
    Prescott WA, Nagel JL.
    Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance.
    Cross AS, Opal S, Kopecko DJ.
    Arch Intern Med; 1983 Nov; 143(11):2075-80. PubMed ID: 6639227
    [Abstract] [Full Text] [Related]

  • 13. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA.
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
    Tsai TY, Chang SC, Hsueh PR, Feng NH, Wang JT.
    J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The evolution of aminoglycoside therapy: a single daily dose.
    Deamer RL, Dial LK.
    Am Fam Physician; 1996 Apr; 53(5):1782-6. PubMed ID: 8623702
    [Abstract] [Full Text] [Related]

  • 18. [Tobramycin. Bacteriological studies and clinical activity in urinary and extra-urinary infections].
    Abbate GF, Alagia I, Gattoni A, Leonessa V, Manguso L, Altucci P.
    G Ital Chemioter; 1977 Apr; 24(1-2):33-7. PubMed ID: 615760
    [No Abstract] [Full Text] [Related]

  • 19. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
    Mars RL, Moles K, Pope K, Hargrove P.
    Adv Perit Dial; 2000 Apr; 16():280-4. PubMed ID: 11045311
    [Abstract] [Full Text] [Related]

  • 20. Tobramycin in the treatment of severe and complicated urinary tract infections.
    Bailey RR, Peddie B.
    N Z Med J; 1976 Jul 14; 84(567):1-3. PubMed ID: 823477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.